Spots Global Cancer Trial Database for Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Official Title: Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Study ID: NCT05150652
Study Description
Brief Summary: The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
Contact Details
Name: Veronica M Jones, MD
Affiliation: University of Kentucky
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
